FDA Brief

Warning letters Drugs

FDA warning letter to

HealBerry

MediumIssued Sep 9, 2025Posted Sep 16, 2025Center for Drug Evaluation and Research (CDER)

FDA warned HealBerry that claiming compounded semaglutide has the 'same active ingredient as Ozempic and Wegovy' misbrands its drugs.

What happened

In August 2025, FDA reviewed HealBerry's website at https://healberry.com and observed that it offers various compounded drug products, including semaglutide. FDA found the website claim 'Same active ingredient as Ozempic and Wegovy.' Because compounded drugs are not FDA-approved, FDA says the claim is false or misleading and misbrands the products.

What FDA found

  1. HealBerry's website claim that its compounded semaglutide has the 'same active ingredient as Ozempic and Wegovy' is false or misleading because compounded drugs are not FDA-approved.

    FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]
  2. The misbranded compounded semaglutide products were introduced or delivered for introduction into interstate commerce.

    FDCA section 301(a) [21 U.S.C. § 331(a)]
  3. Receiving, delivering, or offering delivery of the misbranded drugs in interstate commerce is also prohibited.

    FDCA section 301(c) [21 U.S.C. § 331(c)]

What FDA wants

Within 15 working days of receipt, FDA asks HealBerry to send the Office of Compounding Quality and Compliance a written response describing steps taken to address the violations, prevent recurrence, and include supporting documentation. If HealBerry cannot complete the actions in that time, it must state the reason for delay and when it will finish.

Who should pay attention

  • telehealth companies marketing compounded semaglutide
  • compounding pharmacies and their marketing partners
  • clinicians and brands referring patients to compounded weight-loss drugs

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk